Fludrocortisone Acetate Oral Solution Stability via Non-Aqueous Triglycerides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a stable oral pharmaceutical solution of fludrocortisone acetate is challenging due to its hydrophobic nature and susceptibility to degradation, especially in aqueous and alkaline conditions, making existing solutions unstable and inconvenient for administration.
Innovation Solution
A non-aqueous oral pharmaceutical solution comprising fludrocortisone acetate and medium-chain fatty acid triglycerides, which enhances physicochemical stability by inhibiting hydrolysis and oxidation, and is free from ethanol and other destabilizing agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fludrocortisone acetate is formulated in aqueous solution, then it becomes easier to administer, but it undergoes oxidative rearrangement and degradation at alkaline pH
Solution Approach 1:
The patent changes the pH parameter of the solution from alkaline to acidic range (pH 2-4), which fundamentally alters the stability profile of fludrocortisone acetate. This parameter change prevents oxidative rearrangement and degradation while maintaining the drug's therapeutic efficacy, thus resolving the contradiction between ease of administration and chemical stability
Solution Approach 2:
The patent employs a composite formulation system combining fludrocortisone acetate with specific excipients including hydroxypropyl methylcellulose, sodium lauryl sulfate, and citric acid. This composite approach creates a synergistic effect where the excipients work together to stabilize the drug in aqueous solution at acidic pH, enabling both ease of administration and chemical stability
2Quantity of substance
If fludrocortisone acetate is formulated in alcoholic solution, then it improves solubility, but it undergoes photolytic degradation of the A-ring under UV light or fluorescent lighting
Solution Approach 1:
The patent changes the solvent system parameter from alcoholic to aqueous-based, and simultaneously changes the pH parameter to acidic range. This dual parameter change achieves adequate solubility through the aqueous system and pH control while eliminating the photolytic degradation pathway that occurs in alcoholic solutions, thus resolving the contradiction between solubility and photolytic stability
3Stability of the object's composition
If fludrocortisone acetate is administered as solid tablets, then it ensures stability, but it creates difficulty in swallowing especially for children and the elderly
Solution Approach 1:
The patent transitions the drug formulation from solid phase (tablets) to liquid phase (oral solution). This phase transition fundamentally changes the administration characteristics, making the drug easy to swallow for all patient populations including children and the elderly, while the acidic pH and specific excipients maintain chemical stability in the liquid form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides excellent stability and extended lifetime of fludrocortisone acetate, maintaining less than 1.2% w/w of the active compound and 1.5% w/w of total impurities after three months of storage at 40°C and 75% relative humidity, ensuring effective and stable drug delivery.
Implementation Method 1
Fludrocortisone acetate is a typical example of a hydrophobic therapeutic agent... one conventional approach is to solubilize a hydrophobic therapeutic agent in a bioacceptable triglyceride solvent
Implementation Method 2
in aqueous and alcoholic solutions the a-ketol side chain, as in all such corticosteroids, is prone to oxidative rearrangement and degradation at alkaline pH
Implementation Method 3
the a-ketol side chain, as in all such corticosteroids, is prone to oxidative rearrangement and degradation
Data Source
AI summary
Physicochemically stable oral pharmaceutical solution comprising fludrocortisone acetate and a non-aqueous liquid carrier comprising one or more medium-chain fatty acid triglycerides.